New immune drug IMA401 takes on Hard-to-Treat cancers
Disease control
Ongoing
This early-phase study tests IMA401, a new type of immune therapy that helps the body's T cells attack cancer cells. It is for adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to other treatments. The main goal is to check safety …
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC